Lonza’s Synaffix Collaborates with Qurient Therapeutics to Enable Development of Dual-Payload ADC
- License agreement centered around technology enabling dual-payload ADC
- Unique combination of Synaffix’s exatecan-based technology with Qurient’s CDK7 inhibitor
Amsterdam, The Netherlands and Seongnam-Si, Korea, 25 September 2025 — Synaffix B.V. (“Synaffix”), a Lonza company (SWX:LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with potential best-in-class therapeutic index, today jointly announced that it has entered into a licensing agreement with Qurient Co., Ltd., a clinical-stage biopharmaceutical company based in South Korea, for the development of a dual-payload ADC.
